NewsBenzingaJohnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease Johnson & Johnson Announces Three-Year Data From Its Phase 3 GALAXI 2, 3 Trials Of TREMFYA Demonstrate Efficacy, Consistent Profile To Treat Crohn's Disease Benzinga 2026.10.12 20:12 (GMT+0) Open on Benzinga Other news Here’s How Much You Would Have Made Owning Cenovus Energy Stock In The Last 5 Years 3 Dividend Aristocrat Stocks to Grab Right Now to Get Paid in November - TipRanks.com Here's How Much $100 Invested In Lowe's Companies 15 Years Ago Would Be Worth Today Nowhere to hide: Tech selloff hits software and chip stocks alike 'Anthropic quietly pitches its own AI safety bill to lawmakers'- Politico RELX: The Risk Segment Makes This Buy Less Risky (NYSE:RELX)
